University of Miami's 2nd Biennial Miami Leukemia Symposium
Avatar

2020 Update on CML: What Strategies Can Help Overcome Multi-TKI Resistance or Intolerance?

By University of Miami's 2nd Biennial Miami Leukemia Symposium FEATURING Jorge Cortés
By University of Miami's 2nd Biennial Miami Leukemia Symposium FEATURING Jorge Cortés
144 views
October 23, 2020
0 Comments
Login to view comments. Click here to Login

Featured Video

13:04
Winship Cancer Institute - Emory University

Treatment-Related Quality of Life in MF

Feat. A. Hunter

Featured Video

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay

Related Content

AUTOPLAY
04:16
Luke Fletcher

Efficacy and Safety of Asciminib in Ph+ CML

50:34
Scripps MD Anderson Cancer Center

The Cure of Leukemias in the Next Decade: An Optimist’s View

Feat. H. Kantarjian
07:55
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Treatment Patterns & Clinical Outcomes …

Feat. E. Atallah
09:51
i3 Health

MRD Testing in Leukemias: When Negativity Is a Positive Thing

Feat. N. S. Raje
16:25
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: The New ELN Laboratory Recommendations for the Diagnosis …

Feat. N. Cross
19:15
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: CML - Are We Doing It Right?

Feat. J. Cortés
17:30
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: Rational TKI Choice in CML

Feat. M. Deininger
24:44
Indy Hematology Review

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Feat. R. Birhiray
17:47
The University of Alabama at Birmingham School of Medicine

Treating CML Patients With TKI Resistance vs. TKI Intolerance

Feat. O. Jamy
11:02
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Asciminib Combined With Dasatinib and Predn…

Feat. M. Luskin
17:51
Penn Medicine Cellicon Valley '23: The Future of Cell and Gene Therapies

Chronic GVHD: A Case-Based Discussion

Feat. L. Perry
27:47
City of Hope

Chronic GVHD: Review Advances in Prevention, Novel Endpoints, and Ta…

Feat. I. Amanam
03:03
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Olverembatinib (HQP1351) Overcoming Ponatin…

Feat. E. Jabbour
08:02
ASH 2022 Conference Coverage

ASH 2022 Results From Phase III BMT CTN 1703: Post-Transplant Cyclop…

Feat. S. Holtan
20:43
Indy Hematology Review

Controversies in the Management of CML in 2024

Feat. R. Larson
18:55
International CML Foundation

iCMLf Conversations: CML Clinical Highlights of EHA 2023

Feat. A. Hochhaus
06:26
Akriti Jain

Managing TKI AEs in CML: Thrombocytopenia, Hypertension, Pancreatic …

09:01
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Asciminib + Imatinib, Nilotinib, or Dasatin…

Feat. J. Cortés
30:21
International CML Foundation

ASH 2022 Highlights on CML: Clinical Overview From iCMLf

Feat. M. Mauro
15:52
International CML Foundation

Clinical Updates in CML From ASH 2023

Feat. N. Shanmuganathan